Could cause temporary or reversible harm; serious harm is unlikely.
Failed Moisture Limits: Water (moisture) content above the approved product specifications.
| Brand name | SUNITINIB MALATE |
| Generic name | SUNITINIB MALATE |
| Active ingredient(s) | SUNITINIB MALATE |
| Distributed by / for | Teva Pharmaceuticals USA Inc |
| NDC | 0093-8199-28 |
| Full product label | Sunitinib Malate Capsules, 12.5 mg, 28-count bottles, Rx only, Manufactured By: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, NDC 0093-8199-28 |
| Recalling firm | Teva Pharmaceuticals USA Inc |
| Distribution | Product was distributed to 3 wholesalers/distributors who further distributed the product Nationwide in the USA. |
| Quantity | 180 bottles |
| Recall initiated | 2023-07-05 |
| Report date | 2023-07-19 |
| Recall completed | 2024-01-10 |
| Recall number | D-0913-2023 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Parsippany NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗